RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06437522, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) and other solid tumors confirmed by histopathology and/or cytology;

    Inclusion criterion 5

  3. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

    Inclusion criterion 9

    Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis;

    Exclusion criterion 4

  4. ECOG score 0-1;

    Inclusion criterion 4

  5. No blood transfusion and no use of cell growth factors and/or platelet-raising drugs within 14 days before screening, and the organ function level must meet the requirements;

    Inclusion criterion 8

  6. At least one measurable lesion meeting the RECIST v1.1 definition was required;

    Inclusion criterion 7

  7. Other malignant tumors that progressed or required treatment within 3 years before the first dose;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06437522, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subject volunteered to participate in the study and signed an informed consent;
  • Male or female aged ≥18 years and ≤75 years;
  • Expected survival time ≥3 months;
  • ECOG score 0-1;
  • Patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) and other solid tumors confirmed by histopathology and/or cytology;
  • Patients must provide a documented tumor tissue specimen of the primary or metastatic tumor within 3 years for PD-L1 testing and other testing;
  • At least one measurable lesion meeting the RECIST v1.1 definition was required;
  • No blood transfusion and no use of cell growth factors and/or platelet-raising drugs within 14 days before screening, and the organ function level must meet the requirements;
  • The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  • For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria:

  • Prior treatment with an ADC drug with TOP I inhibitors as a toxin;
  • Before the first delivery within four weeks or five half-life used anti-tumor treatment; Palliative radiotherapy was given within 2 weeks before the first dose;
  • Received any previous systemic antitumor regimen for solid tumors such as recurrent or metastatic head and neck squamous cell carcinoma;
  • Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis;
  • Use of an immunomodulatory drug within 14 days before the first dose of study drug;
  • Systemic corticosteroids were required within 2 weeks before the first dose of the study;
  • Has a history of severe disease of heart head blood-vessel;
  • Active autoimmune and inflammatory diseases;
  • Other malignant tumors that progressed or required treatment within 3 years before the first dose;
  • With ILD requiring steroid treatment, current ILD, or suspected ILD at screening;
  • Presence of: a) poorly controlled diabetes mellitus before study treatment; b) poorly controlled hypertension; c) history of hypertensive crisis or hypertensive encephalopathy;
  • Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  • Patients with active central nervous system metastasis;
  • Patients with pleural effusion, pericardial effusion or ascites with clinical symptoms or requiring repeated drainage;
  • Had allergic history to recombinant humanized antibody or human-mouse chimeric antibody or to any of BL-B01D1's excipients;
  • Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
  • Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;
  • Active infection requiring systemic therapy;
  • Had participated in another clinical trial within 4 weeks before the first dose;
  • Who have a history of psychotropic drug abuse and cannot abstain from it or have mental disorders;
  • Other circumstances that the investigator deemed inappropriate for participation in the trial.

Quoted from ClinicalTrials.gov, NCT06437522, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06437522, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06437522